RNAC · Cartesian Therapeutics, Inc.
$9.99
-0.20 (-1.96%)
At close · Aug 27
Market Cap
$308.30M
Shares
30.26M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 10-Q | 2026-08-06 | 2026-06-30 | |
| 8-K | 2026-08-06 | — | |
| 8-K | 2026-06-17 | 2026-06-12 | |
| 8-K | 2026-06-09 | — | |
| 8-K | 2026-05-26 | 2026-05-22 | |
| Investor Event Transcript | 2026-05-19 | 2026-06-30 | |
| 8-K | 2026-04-30 | — | |
| 10-Q | 2026-04-30 | 2026-03-31 | |
| DEF 14A | 2026-04-28 | 2025-12-31 | |
| Investor Event Transcript | 2026-04-13 | 2026-06-30 | |
| 8-K | 2026-03-30 | 2026-03-26 | |
| 8-K | 2026-03-09 | — | |
| 10-K | 2026-03-09 | 2025-12-31 | |
| 8-K | 2026-01-09 | — | |
| 8-K | 2025-12-18 | 2025-12-16 | |
| 8-K | 2025-11-13 | — | |
| 10-Q | 2025-11-06 | 2025-09-30 | |
| 8-K | 2025-11-06 | — | |
| 8-K | 2025-10-30 | 2025-10-29 | |
| 8-K | 2025-10-21 | 2025-10-15 | |
| 8-K | 2025-10-08 | 2025-10-02 | |
| 8-K | 2025-08-07 | — | |
| 10-Q | 2025-08-07 | 2025-06-30 | |
| 8-K | 2025-06-16 | 2025-06-13 | |
| 8-K | 2025-05-30 | — | |
| 8-K | 2025-05-08 | — | |
| 10-Q | 2025-05-08 | 2025-03-31 | |
| 8-K | 2025-04-29 | — | |
| DEF 14A | 2025-04-28 | 2024-12-31 | |
| 8-K | 2025-04-08 | — | |
| 8-K | 2025-03-13 | — | |
| 10-K | 2025-03-13 | 2024-12-31 | |
| 8-K | 2025-03-03 | — | |
| 8-K | 2025-01-27 | — | |
| 8-K | 2025-01-13 | — | |
| 8-K | 2024-12-03 | — | |
| 8-K | 2024-11-07 | — | |
| 10-Q | 2024-11-07 | 2024-09-30 | |
| 8-K | 2024-09-26 | 2024-09-25 | |
| 8-K | 2024-09-23 | 2024-09-20 | |
| DEF 14A | 2024-08-16 | 2024-09-20 | |
| 10-Q | 2024-08-08 | 2024-06-30 | |
| 8-K | 2024-08-08 | — | |
| 8-K | 2024-07-02 | 2024-07-01 | |
| 8-K | 2024-06-17 | 2024-06-14 | |
| 8-K | 2024-05-22 | — | |
| 8-K | 2024-05-08 | — | |
| 10-Q | 2024-05-08 | 2024-03-31 | |
| DEF 14A | 2024-04-26 | 2023-12-31 | |
| 8-K | 2024-04-22 | 2024-04-19 |
Showing 1–50 of 150 filings
Key facts
CIK
1453687
CUSIP
816212302
13F (30d)
81 filings
80 filers
Visit website
Investor relations